BR112016003511A8 - composição farmacêutica que contém derivado de hidantoína - Google Patents

composição farmacêutica que contém derivado de hidantoína

Info

Publication number
BR112016003511A8
BR112016003511A8 BR112016003511A BR112016003511A BR112016003511A8 BR 112016003511 A8 BR112016003511 A8 BR 112016003511A8 BR 112016003511 A BR112016003511 A BR 112016003511A BR 112016003511 A BR112016003511 A BR 112016003511A BR 112016003511 A8 BR112016003511 A8 BR 112016003511A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
composition containing
hydantoin derivative
containing hydantoin
formula
Prior art date
Application number
BR112016003511A
Other languages
English (en)
Other versions
BR112016003511B1 (pt
BR112016003511A2 (pt
BR112016003511B8 (pt
Inventor
Kitamura Hidetomo
Noda Hiroshi
Tamura Tatsuya
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BR112016003511A2 publication Critical patent/BR112016003511A2/pt
Publication of BR112016003511A8 publication Critical patent/BR112016003511A8/pt
Publication of BR112016003511B1 publication Critical patent/BR112016003511B1/pt
Publication of BR112016003511B8 publication Critical patent/BR112016003511B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção fornece uma composição farmacêutica para induzir uma ação de absorção de osso e/ou cartilagem, que inclui como um componente eficaz da mesma um composto indicado pela fórmula geral (1) ou um sal farmacologicamente aceitável do mesmo: (na fórmula, r1, r2, r3 e r4 são conforme definidos nas reivindicações).
BR112016003511A 2014-06-09 2014-06-09 Composição farmacêutica que contém derivados de hidantoína e uso dos mesmos BR112016003511B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2014/065262 WO2015189901A1 (ja) 2014-06-09 2014-06-09 ヒダントイン誘導体含有医薬組成物

Publications (4)

Publication Number Publication Date
BR112016003511A2 BR112016003511A2 (pt) 2017-08-01
BR112016003511A8 true BR112016003511A8 (pt) 2018-01-30
BR112016003511B1 BR112016003511B1 (pt) 2022-11-08
BR112016003511B8 BR112016003511B8 (pt) 2023-10-03

Family

ID=54833033

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016003511A BR112016003511B8 (pt) 2014-06-09 2014-06-09 Composição farmacêutica que contém derivados de hidantoína e uso dos mesmos

Country Status (10)

Country Link
US (1) US9993462B2 (pt)
EP (1) EP3153166B1 (pt)
KR (2) KR102266021B1 (pt)
CN (2) CN106572994B (pt)
AU (1) AU2014397042B2 (pt)
BR (1) BR112016003511B8 (pt)
CA (1) CA2949023C (pt)
MX (1) MX371090B (pt)
RU (1) RU2701168C2 (pt)
WO (2) WO2015189901A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2930176T3 (pt) * 2012-12-10 2018-07-07
MX2021001063A (es) * 2018-07-30 2021-04-12 Chugai Pharmaceutical Co Ltd Dispersion solida de derivado de hidantoina.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135470A (ja) 1997-07-23 1999-02-09 Teijin Ltd ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤
TR200101644T2 (tr) 1998-12-11 2001-11-21 F.Hoffmann-La Roche Ag TNF-ALFA önleyicileri olarak siklik hidrazin türevleri.
AU2001284412A1 (en) 2000-08-30 2002-03-13 Teijin Limited Parathyroid hormone production inhibitors containing vitamin D3 derivatives
EE200300196A (et) 2000-10-26 2003-10-15 Pfizer Products Inc. Spiropürimidiin-2,4,6-trioonmetalloproteinaasi inhibiitorid
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
JP2007522215A (ja) 2004-02-11 2007-08-09 スミスクライン・ビーチャム・コーポレイション Ｐｔｈアゴニスト
EP1713815A4 (en) 2004-02-11 2009-03-11 Smithkline Beecham Corp PTH AGONISTS
EP1799672B1 (en) * 2004-10-07 2013-01-02 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
WO2007135417A1 (en) 2006-05-19 2007-11-29 James Black Foundation Benzotriazepinone derivatives
CN101472924A (zh) * 2006-06-20 2009-07-01 惠氏公司 Kv1.5钾通道抑制剂
TW200831080A (en) * 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
ATE486058T1 (de) * 2007-06-07 2010-11-15 Hoffmann La Roche Prolinamidderivate als nk3-antagonisten
TWI439462B (zh) 2007-12-10 2014-06-01 Novartis Ag 作為ｅｎａｃ阻抑劑之螺環胍化合物
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
WO2010045229A2 (en) 2008-10-13 2010-04-22 University Of Rochester Protecting and repairing cartilage and musculoskeletal soft tissues
DK2433940T3 (en) 2009-04-28 2015-01-12 Chugai Pharmaceutical Co Ltd Spiroimidazolonderivat
NO2930176T3 (pt) * 2012-12-10 2018-07-07

Also Published As

Publication number Publication date
KR102266021B1 (ko) 2021-06-16
EP3153166A1 (en) 2017-04-12
CN106572994A (zh) 2017-04-19
CN106535892B (zh) 2020-09-18
WO2015190451A1 (ja) 2015-12-17
RU2016113896A3 (pt) 2018-07-18
EP3153166B1 (en) 2022-08-03
CA2949023A1 (en) 2015-12-17
BR112016003511B1 (pt) 2022-11-08
EP3153166A4 (en) 2018-01-17
BR112016003511A2 (pt) 2017-08-01
US9993462B2 (en) 2018-06-12
MX371090B (es) 2020-01-16
CN106572994B (zh) 2020-09-18
BR112016003511B8 (pt) 2023-10-03
MX2016013684A (es) 2017-01-20
RU2016113896A (ru) 2018-07-18
KR20170010439A (ko) 2017-01-31
RU2701168C2 (ru) 2019-09-25
AU2014397042B2 (en) 2020-04-09
WO2015189901A1 (ja) 2015-12-17
KR102382331B1 (ko) 2022-04-01
CA2949023C (en) 2021-10-12
AU2014397042A1 (en) 2016-02-11
US20170112812A1 (en) 2017-04-27
KR20170010354A (ko) 2017-01-31
CN106535892A (zh) 2017-03-22

Similar Documents

Publication Publication Date Title
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
BR112019006712A2 (pt) composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo.
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
BR112017010354A2 (pt) compostos de triazolopirimidina e usos dos mesmos
BR112017010893A2 (pt) análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
BR112016028476A8 (pt) compostos, composição, uso de um composto e método para o combate dos fungos nocivos
SV2016005316A (es) Compuestos y composiciones para inducir condrogénesis
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
EA201692037A1 (ru) Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112015030399B8 (pt) Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3
EA201790570A1 (ru) Модуляторы р2х7
BR112017011316A2 (pt) derivados heterocíclicos e uso destes
NZ748769A (en) Nitroxyl donors with improved therapeutic index
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/06/2014, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2705 DE 08/11/2022, QUANTO AO ITEM (54) TITULO.

B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICACAO DEFERIMENTO (DESPACHO 9.1, RPI 2694).

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2705 DE 08/11/2022 QUANTO AO RELATORIO DESCRITIVO.